india glp-1 Inside OneSource: India’s Next Big Bet On Drugs | Weight Loss Drugs Can India become the pharmacy

It allows for a truly personalized approach to medicine, where treatment can be tailored not just to a diagnosis, but to a patient's most important personal health goals

Tirzepatide lacks glucagon receptor activation, so split dosing preserves more of its efficacy

The problem surfaced in clinical trials run in 1992 by Mojsov and David Nathan, a physician and expert in type 2 diabetes at MGH, and those of Holst and Nauck (Molteni, Chen)

Moreno says

Its very challenging, we think right now, to be able to separate these side effects like nausea from GLP-1's intended effects like weight loss, he added

Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E